Selected class I and class II HLA alleles and haplotypes and risk of high‐grade cervical intraepithelial neoplasia

Human leukocyte antigens (HLAs) present foreign antigens to the immune system and may be important determinants of cervical neoplasia. Previously published associations between HLA and cervical neoplasia exhibit considerable variation in findings. The biomarkers of cervical cancer risk (BCCR) case‐c...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 122; no. 12; pp. 2820 - 2826
Main Authors Ades, Steven, Koushik, Anita, Duarte‐Franco, Eliane, Mansour, Nabil, Arseneau, Jocelyne, Provencher, Diane, Gilbert, Lucy, Gotlieb, Walter, Ferenczy, Alex, Coutlée, François, Roger, Michel, Franco, Eduardo L.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.06.2008
Wiley-Liss
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Human leukocyte antigens (HLAs) present foreign antigens to the immune system and may be important determinants of cervical neoplasia. Previously published associations between HLA and cervical neoplasia exhibit considerable variation in findings. The biomarkers of cervical cancer risk (BCCR) case‐control study addressed the role of specific HLA alleles as cofactors in the development of high‐grade cervical intraepithelial neoplasia (HG‐CIN) based on the most consistent evidence from published literature. Cases (N = 381) were women with histologically‐confirmed HG‐CIN attending colposcopy clinics and controls (N = 884) were women from outpatient clinics with normal cytological screening smears. Subjects were mainly of French‐Canadian descent. Cervical specimens were tested for human papillomavirus (HPV) DNA and HLA genotypes by PGMY L1 consensus primer PCR and a PCR sequence‐specific primer method, respectively. Unlike other studies, the DQB1*03 and DRB1*13 allele groups were not associated with risk of HG‐CIN. The B7‐DRB1*1501‐DQB1*0602 haplotype was associated with a 41% overall reduction in HG‐CIN risk (odds ratio [OR] = 0.59; 95% confidence interval [CI]: 0.36–0.96), and an 83% reduction in risk of HG‐CIN among HPV 16 or HPV 18‐positive subjects (OR = 0.17; 95%CI: 0.05–0.54). Paradoxically, however, the same haplotype was associated with HPV 16/18 infection risk among controls (OR = 8.44, 95%CI: 1.12–63.73). In conclusion, the B7‐DRB1*1501‐DQB1*0602 haplotype was protective against HG‐CIN, especially in individuals infected with oncogenic HPV, but the mechanism of the association seems to involve multiple steps in the natural history of HPV and CIN. © 2008 Wiley‐Liss, Inc.
Bibliography:Members of the BCCR Study Team.
Project manager
Clinical Collaborators
Eliane Duarte‐Franco
Coinvestigators
Study Coordinator
Fax: +514‐398‐5002
François Coutlée, Greg Matlashewski, Michael Pollak, Michel Roger
Anita Koushik
Principal Investigator
Alene Capek, Alex Ferenczy, Audrey Juras, Bertrand Michon, Christine Florakas, Daniel Landry, Danielle Grandmont, Danielle L'Heureux, Diane Provencher, Douglas Dalton, Elsa Queiros, Eric Dauth, Francine Leclerc, Gerald Stanimir, Hing‐Sang Hum, Jean‐Paul Czitrom, Jocelyne Arseneau, Josée Dubuc‐Lissoir, Julien Lord, Lucy Gilbert, Marie‐Hélène Mayrand, Marie‐Josée Dupuis, Markus Martin, Maroussia Roleau, Michel Plamondon, Nabil Mansour, Paul Fournier, Philippe Gauthier, Pierre Drouin, Pierre Fournier, Pierre Jeanbart, Richard Shatz, Robert Piché, Ryan Hunt, Steven Ades.
Eduardo Franco
Solange Piché
Study Nurse
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0020-7136
1097-0215
1097-0215
DOI:10.1002/ijc.23459